- Home
- Signaling Pathways
- Chromatin/Epigenetics
- PARP
- Olaparib (AZD2281, Ku-0059436)
- Home
- Signaling Pathways
- DNA Damage/DNA Repair
- PARP
- Olaparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, Ku-0059436)
Olaparib (4-(3-4-fluorophenyl) methyl-1(2H)-one), as known as AZD2281 or KU0059436, is a novel, selective and potent inhibitor of both poly adenosine diphosphate-ribose polymeras-1 (PARP-1) and poly adenosine diphosphate-ribose polymeras-2 (PARP-2). ?Having been successfully used in the treatment of tumors harboring BRCA mutations, olaparib strongly inhibits the growth of BRCA2-deficient mouse mannary tumor cell lines demonstrating cytotoxicity. In previous researches treating non-small cell lung carcinoma (NSCLC), olaparib increased the radiation sensitivity of NSCLC cells, grown as xenografts in nude mice, following radiation and increased vascular perfusion in Calu-6 tumors established in a dorsal window chamber (DWC) model.
Reference
Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O’Connor, Stephen R. Wedge, and Ian J. Stratford. Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011; 10(10): 1949-1958
Bastiaan Evers, Rinske Drost, Eva Schut, Michiel Bruin, Eline vab der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C. M. Smith, Niall M. B. Martin, Alan Lau, Mark J. O’Connor, and Jos Jonkers. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and Cisplatin. Clin Cancer Res 2008; 14:3916-3925
- 1. Maria V Sukhanova, Rashid O Anarbaev, et al. "Biologically Relevant Polyamines, Divalent Metal Cations, and Structure of Poly(ADP-Ribose) All Control Microphase Separation of FUS with Poly(ADP-Ribosyl)ated PARP1." Biology and Life Sciences. 03 October 2024
- 2. Maria V Sukhanova, Rashid O Anarbaev, et al. "Divalent and multivalent cations control liquid-like assembly of poly (ADP-ribosyl) ated PARP1 into multimolecular associates in vitro." Commun Biol. 2024 Sep 15;7(1):1148 PMID: 39278937
- 3. Yinan Jiang, Shuting Huang, et al. "Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer." MedComm (2020). 2024 Apr 13;5(4):e537. PMID: 38617434
- 4. Apoorva Uboveja, Zhentai Huang, et al. "αKG-mediated carnitine synthesis promotes homologous recombination via histone acetylation." bioRxiv. 2024 Feb 11:2024.02.06.578742 PMID: 38370789
- 5. Andrew N. Blackford, et al. "BLM and BRCA1-BARD1 coordinate complementary mechanisms of joint DNA molecule resolution." Mol Cell. 2024 Feb 15;84(4):640-658.e10. PMID: 38266639
Storage | Store at -20°C |
M.Wt | 434.46 |
Cas No. | 763113-22-0 |
Formula | C24H23FN4O3 |
Synonyms | AZD 2281,AZD-2281 |
Solubility | ≥21.72 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
Chemical Name | 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one |
SDF | Download SDF |
Canonical SMILES | C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Cell experiment: [1] | |
Cell lines |
Normal LCL cells ATM-null LCL cells |
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reaction Conditions |
10 μM, 1 hour |
Applications |
The sensitivity of cells to olaparib is mediated by absence of Ataxia Telangiectasia Mutated (ATM) activity. Immunoblot analysis revealed that in ATM wild-type LCLs, but not ATM null LCLs, phosphorylation of the ATM-dependent targets ATM S1981 and SMC1 S966 was induced in a dose-dependent manner by olaparib. |
Animal experiment: [1] | |
Animal models |
Granta-519–engrafted NOD/SCID mice |
Dosage form |
Intraperitoneal injection, 50 mg/kg/d, for 14 days |
Applications |
Analysis of the percentage of human CD45 staining by FACS analysis revealed a significant reduction in the percentage of Granta-519 cells in the bone marrow and a trend toward reduced tumor cell load in the spleen of mice treated with olaparib compared with those receiving vehicle alone. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Weston V J, Oldreive C E, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood, 2010, 116(22): 4578-4587. |
Olaparib (AZD2281, KU0059436) is a potent inhibitor of PARP1 and PARP2 with IC50 of 5 and 1 nM, respectively. | ||||||
Targets | PARP1 | PARP2 | ||||
IC50 | 5 nM | 1 nM |
Quality Control & MSDS
- View current batch:
Chemical structure

Related Biological Data

Related Biological Data

Related Biological Data

Related Biological Data

Related Biological Data

Related Biological Data

Related Biological Data
